GleamWall
中文EN

ALKS Alkermes plc.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1520262 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY15.3%
TTM net income YoY-100.1%
TTM EPS YoY-100.5%
Revenue 3-yr CAGR3.3%
Net income 3-yr CAGR—

Margins

Gross margin82.9%
Operating margin3.7%
Net margin-0.0%
FCF margin13.0%
EBITDA margin8.3%

Returns

ROE-0.0%
ROA-0.0%
ROIC (approx.)1.7%
Asset turnover0.52x

Leverage & solvency

Liabilities / assets58.0%
Debt / equity0.80x
Current ratio2.42x
Interest coverage0.74x

Cash quality & payout

Operating cash flow / net income-692.27x
Accruals ratio-7.2%
Payout ratio—
Capex / revenue0.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31
Income statement
Revenue$1.48B$1.56B
Cost of revenue$196.46M$245.33M
Gross profit$1.28B$1.31B
R&D expense$323.96M$245.33M
SG&A expense$701.52M$645.24M
Operating income$253.96M$420.64M
Interest expense$12.28M$22.58M
Pretax income$291.45M$443.75M
Income tax$49.79M$71.61M
Net income$241.66M$367.07M
EBITDA$281.12M$449.17M
EPS (basic)1.472.22
EPS (diluted)1.432.17
Weighted avg. shares (diluted)168.74M169.20M
Balance sheet
Cash & equivalents$388.57M$291.15M
Short-term investments$199.65M$460.52M
Receivables$334.02M$384.53M
Inventory$196.62M$182.89M
Current assets$1.93B$1.42B
PP&E, net$221.72M$227.56M
Goodwill$83.03M$83.03M
Intangibles$815,000$890,000
Total assets$2.49B$2.06B
Current liabilities$543.44M$465.20M
Short-term debt$0—
Long-term debt$0—
Total debt$0—
Total liabilities$667.70M$590.59M
Shareholders' equity$1.82B$1.46B
Net debt-$388.57M—
Shares outstanding165.61M162.18M
Cash flow statement
Operating cash flow$520.75M$439.12M
Capital expenditure$40.42M$33.48M
Free cash flow$480.33M$405.64M
Investing cash flow$295.50M-$111.31M
Financing cash flow$12.38M-$494.14M
Depreciation & amortization$27.16M$28.53M
Stock-based compensation$98.72M$96.64M
Share buybacks—$200.28M

Free plan shows the latest 2 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.